Lekost Tablet contains Levocetirizine 5 mg and Montelukast 10 mg, combining an antihistamine and a leukotriene receptor antagonist to effectively manage allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal congestion, and itching associated with allergic rhinitis and chronic urticaria. Montelukast acts by blocking leukotriene D4 receptors in the airway, preventing bronchoconstriction, inflammation, and mucus production, making it beneficial in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from allergic manifestations by targeting multiple inflammatory pathways. Lekost Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision in pregnant or lactating women. Dosage and duration of therapy should be individualized based on clinical response and severity of symptoms.